Objective: Minimally invasive surgery is increasingly adopted as an alternative to conventional sternotomy for mitral valve pathology in many centres worldwide. A systematic safety analysis based on a comprehensive list of pre-specified 30-day complications defined by the Mitral Valve Academic Consortium (MVARC) criteria is lacking. The aim of the current study was to systematically analyse the safety of minimally invasive mitral valve surgery in our centre based on the MVARC definitions. Methods: All consecutive patients undergoing minimally invasive mitral valve surgery through right mini-thoracotomy in our institution within 10 years were studied retrospectively. The primary outcome was a composite of 30-day major complications based on MVARC definitions. Results: 745 patients underwent minimally invasive mitral valve surgery (507 repair, 238 replacement), with a mean age of 62.9±12.3 years. The repair was successful in 95.8%. Overall 30-day mortality was 1.2% and stroke rate 0.3%. Freedom from any 30-day major complications was 87.2%, and independent predictors were left ventricular ejection fraction <50% (OR 1.78; 95% CI 1.02 to 3.02) and estimated glomerular filtration rate <60 mL/min/1.73 m2 (OR 1.98; 95% CI 1.17 to 3.26). Conclusions: Minimally invasive mitral valve surgery is a safe technique and is associated with low 30-day mortality and stroke rate.
A systematic search on Medline, Embase, and Cochrane resulted in 19 retrospective studies (published from 2010-2020) reporting SIFs in the work-up for TAVI.
Minimally invasive mitral valve surgery is evolving rapidly since the early 1990’s and is now increasingly adopted as the standard approach for mitral valve surgery. It has a long and challenging learning curve and there are many considerations regarding technique, planning and patient selection when starting a minimally invasive program. In the current review, we provide an overview of all considerations and the decision-making process during the learning curve.
1 January 2022 in Seminars in Thoracic and Cardiovascular Surgery
In this case report, we describe the feasibility and technical considerations of an off-label use of the new Gore ® Aortic Extender (W.L. Gore & Associates), which is part of the Gore ® TAG ® Thoracic Branch Endoprosthesis (W.L. Gore & Associates), to repair a huge false aneurysm originating from an ascending aortic prosthesis. The patient’s medical history reported an acute type A aortic dissection 10 years ago, for which he was treated with a Bentall procedure. This was complicated by obstruction of the left main coronary after it was reconstructed and thus a coronary artery bypass was also performed. During follow-up, a huge false aneurysm of 11 cm was found, caused by a dehiscent saphenous vein graft on the Bentall prosthesis. Since the patient was clearly not fit for redo surgery, we decided to treat this patient endovascularly with the Gore ® Aortic Extender (W.L. Gore & Associates). This cuff has recently been introduced and is off-the-shelf available and seemed to fit perfectly in this patient. Clinical impact: With the introduction of the new, Gore ® TAG ® Thoracic Branch Endoprosthesis (W.L. Gore & Associates), a very short endoprosthesis became available for proximal extension of the Thoracic Branch Endoprosthesis. This graft, the Gore ® Aortic Extender (W.L. Gore & Associates) seems to come in favorable sizes for the ascending aorta. As long as dedicated endoprosthesis for the ascending aorta are not off-the-shelf availabe, off-label use of such endovascular devices is an useful option whenever open surgery seems too high risk.